MXPA02006251A - Composiciones y metodos para l-nucleosidos, l-nucleotidos y sus analogos. - Google Patents

Composiciones y metodos para l-nucleosidos, l-nucleotidos y sus analogos.

Info

Publication number
MXPA02006251A
MXPA02006251A MXPA02006251A MXPA02006251A MXPA02006251A MX PA02006251 A MXPA02006251 A MX PA02006251A MX PA02006251 A MXPA02006251 A MX PA02006251A MX PA02006251 A MXPA02006251 A MX PA02006251A MX PA02006251 A MXPA02006251 A MX PA02006251A
Authority
MX
Mexico
Prior art keywords
compound
contemplated
ribavirin
antiviral
type
Prior art date
Application number
MXPA02006251A
Other languages
English (en)
Spanish (es)
Inventor
Robert Tam
Original Assignee
Ribapharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribapharm Inc filed Critical Ribapharm Inc
Publication of MXPA02006251A publication Critical patent/MXPA02006251A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
MXPA02006251A 1999-12-23 2000-12-19 Composiciones y metodos para l-nucleosidos, l-nucleotidos y sus analogos. MXPA02006251A (es)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US17209799P 1999-12-23 1999-12-23
US17344699P 1999-12-29 1999-12-29
US17511100P 2000-01-06 2000-01-06
US19075800P 2000-03-20 2000-03-20
US22694700P 2000-08-22 2000-08-22
US22687500P 2000-08-22 2000-08-22
US23382300P 2000-09-19 2000-09-19
US23382200P 2000-09-19 2000-09-19
US23354800P 2000-09-19 2000-09-19
US23382100P 2000-09-19 2000-09-19
US23546500P 2000-09-26 2000-09-26
PCT/US2000/034605 WO2001045509A1 (en) 1999-12-23 2000-12-19 Compositions and methods for l-nucleosides, l-nucleotides, and their analogs

Publications (1)

Publication Number Publication Date
MXPA02006251A true MXPA02006251A (es) 2003-01-28

Family

ID=27582702

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02006251A MXPA02006251A (es) 1999-12-23 2000-12-19 Composiciones y metodos para l-nucleosidos, l-nucleotidos y sus analogos.

Country Status (20)

Country Link
EP (1) EP1244356A4 (ja)
JP (1) JP2003523957A (ja)
KR (1) KR20030032908A (ja)
CN (1) CN1420723A (ja)
AU (1) AU2442201A (ja)
BR (1) BR0016162A (ja)
CA (1) CA2384326A1 (ja)
CZ (1) CZ20022112A3 (ja)
HK (1) HK1049944A1 (ja)
HR (1) HRP20020485A2 (ja)
HU (1) HUP0300219A3 (ja)
IL (1) IL148514A0 (ja)
MX (1) MXPA02006251A (ja)
NO (1) NO20022969D0 (ja)
NZ (1) NZ517634A (ja)
PL (1) PL364927A1 (ja)
SI (1) SI20976A (ja)
SK (1) SK8612002A3 (ja)
WO (1) WO2001045509A1 (ja)
YU (1) YU47802A (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
CN1863812A (zh) 2003-09-11 2006-11-15 弗·哈夫曼-拉罗切有限公司 多晶型核苷化合物
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
CN101511185A (zh) * 2006-09-11 2009-08-19 南方研究所 唑类核苷和作为rna和dna病毒聚合酶抑制剂的用途
CN102952104A (zh) * 2011-08-17 2013-03-06 黑龙江省松花江药业有限公司 一种呋喃类化合物
CN106061984A (zh) 2014-02-13 2016-10-26 配体药物公司 前药化合物及其用途
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
CN104387431A (zh) * 2014-10-24 2015-03-04 江南大学 一种高特异性的利巴韦林人工抗原的制备方法
EP3156050A1 (en) * 2015-10-16 2017-04-19 Universitat Autònoma De Barcelona New combination therapies for treating neurological damage
CA3087932A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
CN109528638B (zh) * 2018-12-20 2021-07-06 江西润泽药业有限公司 利巴韦林衍生物制剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
EP0262125B1 (en) * 1986-03-27 1996-03-27 Gensia, Inc. AICA riboside for the prophylactic treatment of diseases with restricted blood flow.
GB9019812D0 (en) * 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5981507A (en) * 1995-12-14 1999-11-09 Advanced Magnetics, Inc. Polymeric carriers linked to nucleotide analogues via a phosphoramide bond
PL187107B1 (pl) * 1996-10-16 2004-05-31 Icn Pharmaceuticals L-nukleozydy monocykliczne, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie
ES2172288T3 (es) * 1998-05-15 2002-09-16 Schering Corp Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
WO2000030656A1 (en) * 1998-11-20 2000-06-02 The Salk Institute For Biological Studies Neuron stimulation by ribavirin, and analogs thereof

Also Published As

Publication number Publication date
NZ517634A (en) 2004-06-25
EP1244356A1 (en) 2002-10-02
CZ20022112A3 (cs) 2003-05-14
YU47802A (sh) 2006-03-03
CA2384326A1 (en) 2001-06-28
BR0016162A (pt) 2002-08-13
AU2442201A (en) 2001-07-03
EP1244356A4 (en) 2003-03-19
HUP0300219A2 (hu) 2003-06-28
WO2001045509A1 (en) 2001-06-28
JP2003523957A (ja) 2003-08-12
NO20022969L (no) 2002-06-20
PL364927A1 (en) 2004-12-27
HRP20020485A2 (en) 2005-10-31
CN1420723A (zh) 2003-05-28
NO20022969D0 (no) 2002-06-20
HUP0300219A3 (en) 2005-07-28
SI20976A (sl) 2003-02-28
KR20030032908A (ko) 2003-04-26
HK1049944A1 (zh) 2003-06-06
SK8612002A3 (en) 2003-03-04
IL148514A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
US5872104A (en) Combinations and methods for reducing antimicrobial resistance
US6815542B2 (en) Nucleoside compounds and uses thereof
US20200147117A1 (en) Combination cancer therapy
US6495677B1 (en) Nucleoside compounds
EP1257281B8 (en) Nucleoside analogs with carboxamidine modified monocyclic base
MXPA02006251A (es) Composiciones y metodos para l-nucleosidos, l-nucleotidos y sus analogos.
US20050009767A1 (en) Use of ribofuranose derivatives against inflammatory bowel diseases
US6911435B1 (en) Method of treating leukopenia with adenosine
JP2506323B2 (ja) 低減された毒性の薬剤調製物
Alexander et al. Lipid nucleoside conjugates for the treatment of cancer
US20170071965A1 (en) Antimetabolite agent combinations in the treatment of cancer
CA2123780A1 (en) Amphotericin b composition with enhanced antifungal activity
US6541462B1 (en) Sphingomyelin enhancement of tumor therapy
US5175005A (en) Method of controlling lung tumor cell metastasis
KR20030040415A (ko) 질병의 치료시에 특이성을 향상시키는 방법
US20040014696A1 (en) Specificity in treatment of diseases
CN114939169A (zh) 一种烟酰胺磷酸核糖转移酶抑制剂的新用途
EP3010513B1 (en) Combination of ro5503781 and capecitabine for cancer therapy
WO2004073719A1 (en) A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent
ZA200206468B (en) Nucleoside analogs with carboxamidine modified monocyclic base.